Company profile
ALX ONCOLOGY HOLDINGS INC
NASDAQ:ALXOBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| EVORPACEPT | phase2_3 | — | 8 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (9)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07085091 | phase1 | recruiting | 2025-08-18 | 2027-06-01 | ALX Oncology Inc. | A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors |
| NCT04417517 | phase1 | terminated | 2020-10-02 | 2025-01-17 | ALX Oncology Inc. | A Study of Evorpacept (ALX148) With Azacitidine for Higher Risk Myelodysplastic Syndrome (ASPEN-02) |
| NCT05524545 | phase1 | completed | 2022-11-02 | 2025-06-27 | ALX Oncology Inc. | A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07) |
| NCT04755244 | phase1 | terminated | 2021-05-05 | 2023-05-05 | ALX Oncology Inc. | A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05) |
| NCT05002127 | phase2_3 | active_not_recruiting | 2022-01-15 | 2024-05-24 | ALX Oncology Inc. | A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06) |
FDA applications (0)
No records yet.